MedTrace Logo

Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

NCT02065778 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-25

No results posted yet for this study

Summary

The purpose of this study was to study the safety and effect of stem cell therapy on the functional recovery in patients with chronic stroke.

Conditions

  • Cerebrovascular Accident

Interventions

BIOLOGICAL

Autologous bone marrow mononuclear cell transplantation

bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients

Sponsors & Collaborators

  • Neurogen Brain and Spine Institute

    lead OTHER

Principal Investigators

  • Alok K Sharma, M.S., M.Ch · Neurogen Brain and Spine Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-07-31
Completion
2014-01-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02065778 on ClinicalTrials.gov